ST 501
Alternative Names: ST-501; Tau targeting ZFP TF-Sangamo TherapeuticsLatest Information Update: 18 Mar 2024
At a glance
- Originator Sangamo Therapeutics
- Developer Biogen; Sangamo Therapeutics
- Class Antidementias; Gene therapies; Zinc finger DNA binding proteins
- Mechanism of Action Genetic transcription inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 13 Mar 2024 Sangamo Therapeutics intends to submit an IND application to the US FDA for Alzheimer’s disease in the fourth quarter of 2025
- 29 Feb 2024 Preclinical trials in Alzheimer's disease in USA (IV) (Sangamo Therapeutics Pipeline, February 2024)
- 15 May 2023 Discontinued - Preclinical for Alzheimer's disease in USA (IV) (Sangamo Therapeutics pipeline; May 2023)